Active Filter(s):
Details:
Company received positive feedback from FDA as the it prepares to advance its lead program into Phase 3, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia using its Hair Follicle Neogenesis device.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020